Aprea Therapeutics, Inc. 是一間臨床階段生物製藥公司,開發及銷售可重新激活突變型 p53 腫瘤抑制蛋白的癌症療法。公司總部位於麻薩諸塞州波士頓。
財務指標
營業收入
2026-06-30
$0
2026-03-31
$0
2025-12-31
$3.33K
2025-09-30
$1.84K
營業支出
2026-06-30
$4.03M
2026-03-31
$3.42M
2025-12-31
$2.64M
2025-09-30
$3.11M
淨利潤
2026-06-30
-$3.59M
2026-03-31
-$3.28M
2025-12-31
-$2.45M
2025-09-30
-$2.97M
淨利潤率
2026-06-30
--
2026-03-31
--
2025-12-31
-73.58K%
2025-09-30
-160.84K%
每股收益
2026-06-30
$-0.07
2026-03-31
$-0.22
2025-12-31
$-0.32
2025-09-30
$-0.47
息稅折舊攤銷前利潤
2026-06-30
-$3.58M
2026-03-31
-$3.28M
2025-12-31
-$2.45M
2025-09-30
-$2.96M
有效稅率
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
項目
2026-06-30
2026-03-31
2025-12-31
2025-09-30
營業收入
$0
$0
$3.33K
$1.84K
營業支出
$4.03M
$3.42M
$2.64M
$3.11M
淨利潤
-$3.59M
-$3.28M
-$2.45M
-$2.97M
淨利潤率
--
--
-73.58K%
-160.84K%
每股收益
$-0.07
$-0.22
$-0.32
$-0.47
息稅折舊攤銷前利潤
-$3.58M
-$3.28M
-$2.45M
-$2.96M
有效稅率
--
--
--
--
常見問題
APRE stock represents shares of a publicly traded company listed on a U.S. stock exchange. The ticker APRE identifies that specific company in market data systems, allowing investors to track its price, trading volume, and corporate announcements. The latest APRE quote and profile information are shown on this page, including the company's name, sector, and primary business operations, so investors can confirm exactly which entity the ticker refers to.
APRE's share price can respond to company-specific developments such as quarterly earnings, guidance changes, management decisions, and new contracts, as well as broader market conditions. Sector trends, interest rates, inflation data, and overall investor sentiment toward small-cap or micro-cap stocks may also influence trading. Because APRE may trade with limited liquidity, relatively small order flows can sometimes move the price more than they would for a large-cap stock.
Recent performance is best measured using the live quote and chart on this page, which show APRE's latest price, daily change, and short-term trend. Performance over weeks or months can be compared against prior closing prices, the 52-week range, and relevant index benchmarks. Reviewing both price movement and trading volume together can help investors judge whether recent activity reflects broad interest or thin, isolated trades.
Valuation analysis for APRE typically involves comparing its market capitalization, price-to-sales, price-to-book, or price-to-earnings ratios with peers in the same industry. Because ratios depend on current price and reported financials, the most reliable figures are those displayed on this page and in APRE's latest filings. Investors often look at whether APRE is profitable, its growth rate, and its cash position to judge whether the market price is reasonable.
Start with APRE's quarterly and annual reports, focusing on revenue trends, gross margin, operating income, net income, and cash flow from operations. Comparing these figures across several periods shows whether the business is growing or contracting. Balance sheet items such as cash, debt, and shareholder equity help assess financial stability. Earnings releases and SEC filings provide the underlying numbers that support any deeper analysis of APRE.
APRE may carry risks common to smaller publicly traded companies, including limited liquidity, higher price volatility, dependence on a narrow customer or product base, and potential financing needs. If the company is not consistently profitable, it may rely on capital raises that dilute existing shareholders. Market-wide downturns, sector-specific pressures, and execution risks can also weigh on the stock. Reviewing APRE's risk disclosures in its filings can clarify which of these apply.